A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

A cancer diagnosis has hit very close to home in recent months. It’s likely that cancer has also struck close to most of ...

A new study from researchers in France has found that taking high doses of vitamin D every two weeks may help reduce disease ...

It took a decade for Heather Castellani Milboer to be diagnosed with multiple sclerosis. Now, she helps build community for ...

McDonald Criteria revisions around 30% of patients with atypical clinical symptoms or radiological-only presentation meet MS ...

Gabryelle “Gabby” Scholfield, a 16-year-old student-athlete at Edmondson Westside High School in Baltimore, who plays center ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...

Paris: A French study has revealed that taking vitamin D3 (cholecalciferol) orally at a dose of 100,000 international units ...

US FDA accepts for priority review Sanofi’s regulatory submission of tolebrutinib for patients with multiple sclerosis: Paris Wednesday, March 26, 2025, 09:00 Hrs [IST] The US F ...

FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to ...

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...